Cisarovsky Christophe, Latifyan Sofiya, Perrinjaquet Claire, Berthold Dominik, Orcurto Angela
Service d'oncologie médicale, Département d'oncologie, CHUV, 1011 Lausanne.
Service d'immuno-oncologie, Département d'oncologie, CHUV, 1011 Lausanne.
Rev Med Suisse. 2021 May 19;17(739):974-977.
Intravesical immunotherapy with Calmette-Guerin bacillus (BCG) have been used since decades for the treatment of non-muscle invasive bladder cancer and is a proof of principle that immunotherapy works for this malignancy. Since 2016, immune checkpoint inhibitors (ICI) demonstrated clinical benefits in locally advanced or metastatic bladder cancer, providing potentially durable tumor control in first line therapy or upon relapse after standard treatments. Ongoing clinical trials aim to demonstrate the efficiency of ICI for the treatment of localized disease.
